ProMIS Neurosciences Inc
TSX:PMN
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/GP
Enterprise Value to Gross Profit (EV/GP) ratio compares a company`s total enterprise value to its gross profit. It shows how much investors are paying for each dollar of the company`s gross profit, including both equity and debt.
Enterprise Value to Gross Profit (EV/GP) ratio compares a company`s total enterprise value to its gross profit. It shows how much investors are paying for each dollar of the company`s gross profit, including both equity and debt.
Valuation Scenarios
If EV/GP returns to its Industry Average (7), the stock would be worth CA$0 (100% downside from current price).
| Scenario | EV/GP Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 0 | CA$6 |
0%
|
| Industry Average | 7 | CA$0 |
-100%
|
| Country Average | 6.6 | CA$0 |
-100%
|
Forward EV/GP
Today’s price vs future gross profit
Peer Comparison
| Market Cap | EV/GP | P/E | ||||
|---|---|---|---|---|---|---|
| CA |
|
ProMIS Neurosciences Inc
TSX:PMN
|
51.5m CAD | 0 | -1.8 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 0 | -160 127.7 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
373.6B USD | 9.8 | 89.2 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
186.6B USD | 7.5 | 24.2 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
162.4B USD | 7.5 | 19.1 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 769.8 | -533.6 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
108.6B USD | 9.7 | 27.5 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
74.7B USD | 4.3 | 16.6 | |
| NL |
|
argenx SE
XBRU:ARGX
|
41.3B EUR | 11.9 | 37.4 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 26 | -61.8 | |
| AU |
|
CSL Ltd
ASX:CSL
|
60B AUD | 6.4 | 29.6 |
Market Distribution
Other Multiples
ProMIS Neurosciences Inc
Glance View
ProMIS Neurosciences Inc is a CA-based company operating in Biotechnology industry. The company is headquartered in Toronto, Ontario and currently employs 5 full-time employees. The company went IPO on 2005-09-30. ProMIS Neurosciences, Inc. is a Canada-based development-stage biotechnology company. The firm is focused on the discovery and development of precision medicine solutions for early detection and effective treatment of neurodegenerative diseases, including Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and Parkinson’s disease (PD). The firm is focused on the discovery engine, which is based on the use of two complementary algorithms: ProMIS and Collective Coordinates, which are used to predict targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. The firm is focused on developing antibody therapeutics for AD, ALS and PD. The firm has a wholly owned subsidiary is ProMIS Neurosciences (US) Inc. (ProMIS USA).
